Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | LPL | P06858 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8638622 | 0.89 | TAAR1 (0.34) | RIPK1CNR1CNR2PKMNPC1 | |
| SCHEMBL9295577 | 0.85 | HPGD (0.48) | NPC1RAB9AHSD17B10PTGS2CYP3A4 | |
| SCHEMBL27959518 | 0.83 | PTGS2 (0.54) | NPC1RAB9ATP53HSD17B10PTGS2 | |
| SCHEMBL16105773 | 0.83 | CES2 (0.39) | RIPK1RAPGEF4MAOBPTGS2CES2 | |
| SCHEMBL17487563 | 0.82 | LPL (0.36) | CNR1CNR2PKMNPC1RAB9A | |
| SCHEMBL19703013 | 0.82 | MAOB (0.43) | PKMNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL18891839 | 0.81 | PTGS2 (0.55) | TP53HSD17B10PTGS2CYP3A4 | |
| SCHEMBL13064228 | 0.81 | HTR2A (0.42) | RIPK1CYP3A4NOS3NOS1NOS2 | |
| SCHEMBL13548301 | 0.81 | ALDH1A1 (0.46) | PTGS2CYP3A4MAPK1 | |
| SCHEMBL17487407 | 0.81 | CTSL (0.36) | RIPK1MAOBPTGS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2023195529-A1 | URACIL DERIVATIVE HAVING VIRAL GROWTH INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 塩野義製薬株式会社 | 2023-10-12 | — | — | WO | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-20230309388-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-11572364-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220127266-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-04-28 | — | — | US | disclosed |
| US-11225480-B2 | Malic enzyme inhibitors | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-01-18 | — | — | US | disclosed |
| US-11059826-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2021-04-22 | — | — | US | disclosed |
| WO-2021074898-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2021-04-22 | — | — | WO | disclosed |
| US-RE42013-E1 | Macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. (CA) | 2010-12-28 | — | — | US | disclosed |
| US-20090221689-A1 | Macrocyclic Modulators of the Ghrelin Receptor | TRANZYME PHARMA INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090170757-A1 | METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | TRANZYME PHARMA INC. | 2009-07-02 | — | — | US | disclosed |
| US-7491695-B2 | Therapy for endocrime disorders; gastrointestinal disorders; cardiovascular disorders; obesity; central nervous system disorders; antiproliferative agents ; using growth hormone secretagogue receptor | TRANZYME PHARMA INC. (CA) | 2009-02-17 | — | — | US | disclosed |
| US-7476653-B2 | Using growth hormone secretagague receptors; endocrime disorders; gastrointestinal disorders; cardiovascular disorders; central nervous system disorders; antiproliferative agents; antiinflammatory agents | TRANZYME PHARMA, INC. (CA) | 2009-01-13 | — | — | US | disclosed |
| US-20080167352-A1 | Sphingosine Kinase Inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
| US-7338961-B2 | Sphingosine kinase inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221689-A1 | Macrocyclic Modulators of the Ghrelin Receptor | GHSR, GIPR, GHRHR | RIPK1 1856/4885CNR1 180/4885CNR2 287/4885 |
| US-20090170757-A1 | METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | GHSR, GHRHR, GIPR | RIPK1 2459/4885CNR1 166/4885CNR2 252/4885 |
| US-11572364-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | RIPK1 3424/4885CNR1 2459/4885CNR2 3006/4885 |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | SPHK1, SPHK2, S1PR2 | RIPK1 158/4885CNR1 1246/4885CNR2 884/4885 |
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | RIPK1 2622/4885CNR1 4716/4885CNR2 4796/4885 |
| US-11225480-B2 | Malic enzyme inhibitors | ME1, RNASE1, ME2 | RIPK1 3282/4885CNR1 3579/4885CNR2 4520/4885 |
| US-20220127266-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | RIPK1 2622/4885CNR1 4716/4885CNR2 4796/4885 |
| US-11059826-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | RIPK1 3424/4885CNR1 2459/4885CNR2 3006/4885 |
| US-20080167352-A1 | Sphingosine Kinase Inhibitors | SPHK1, SPHK2, S1PR1 | RIPK1 55/4885CNR1 1055/4885CNR2 952/4885 |
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | RIPK1 3349/4885CNR1 423/4885CNR2 373/4885 |
| US-20230309388-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE | OCIAD1, OCIAD2, SLCO4C1 | RIPK1 2813/4885CNR1 3973/4885CNR2 4157/4885 |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | GHSR, GHRHR, GIPR | RIPK1 2459/4885CNR1 166/4885CNR2 252/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | RIPK1 3424/4885CNR1 2459/4885CNR2 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.